Abstract Library

#4248 Tryptophan pathway metabolites as prognostic biomarkers of recurrent disease in curatively operated neuroendocrine tumor patients

Introduction: The majority of NET patients experience recurrent disease after curative surgery. There is a need for prognostic biomarkers in this patient group.

Conference:

Presenting Author: Johansen S

Authors: Johansen S, Hansen T, Goll R, Florholmen J,

Keywords: Plasma Tryptophan Metabolites, Prognostic Biomarker, Recurrent Disease after Curative Surgery,

#3632 Medullary thyroid carcinoma and somatostatin analogues, a possible therapeutic choice in asymptomatic and slow radiological progression metastatic recurrent disease after surgery – Case report of a 22-years long term survival patient

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor of the thyroid and accounts for 1%-2% of thyroid cancers in the United States. MTCs present with locoregional metastasis in 50% of patients and distant metastasis in 10%-15% at diagnosis. Treatment options for recurrent or progressive disease according to RECIST 1.1 criteria, are limited. Tyrosine kinase-inhibitors (TKI) are preferred as first-line systemic therapy. Although somatostatin analogues (SSA) may play a role in MTC, limited evidence is available.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Maratta M, Giampietro A, de Marinis L,

Keywords: medullary thyroid carcinoma (MTC), somatostatin analogues, survival,

#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Landoni L, Nessi C, Muffatti F,

Keywords: pancreatic neuroendocrine tumors, recurrence, surgery, locoregional treatment, systemic treatment,

#1677 A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Non-Functional Pancreatic Neuroendocrine Tumors.

Introduction: Surgical resection is the preferred treatment for NF-pNET, however recurrence still occurs frequently after curative surgery, worsening prognosis of patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Genc C

Authors: Genc C, Jilesen A, Partelli S, Falconi M, Muffatti F,

Keywords: pNET, recurrence, predictive-model.,

#1567 Pancreatic Neuroendocrine Tumors: Experience from a Single Institute

Introduction: A dedicated multidisciplinary team is necessary in the management of pancreatic neuroendocrine tumor (pNET).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Caff A, Cordio S, Pellegriti G, Russo M, Trovato M,

Keywords: pancreatic, Ki-67,